WuXi's manufacturing boom spells a big quarter

WuXi PharmaTech ($WX), China's largest CRO, boosted its revenue by 14.8% in the second quarter, as banner growth in its contract manufacturing business helped the company expand its global reach.

Sales came in at $163.4 million on the quarter, beating out the prior year's $142.3 million. The CRO's lab services business jumped 13.2% to $119.9 million, driven by 14.2% growth in its Chinese services arm and a 9.6% jump in its U.S. operation. Manufacturing services, WuXi's fastest-growing segment, leapt 19.3% in the second quarter, bringing in $43.5 million.

WuXi credits its success to escalating demand for its discovery services and a broad-based expansion of its manufacturing platform. The CRO has now upped the lower end of its full-year expectations, forecasting between $665 million and $670 million in 2014, good for up to 16% annual growth.

The company is also dialing up how much it plans to spend on M&A and internal investments, earmarking up to $100 million for capital expenditures, an 18% increase over previous guidance and almost double what it spent in 2013.

"We remain committed to building the premier open-access R&D platform that enables anyone and any company to discover and develop innovative medicines to benefit the world's patients," CEO Ge Li said in a statement.

- read the results

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.